Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Image-Guided Surgery for Prostate Cancer Using C' dot Tracers
NCT04167969Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2021
- Primary completion
- Nov 2027
- Modality
- Nanoparticles, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots and 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Side effects at 1 year. Started Feb 2021; status: recruiting.
02
Drugs
copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04167969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167969.